ArticleJournal of the American Society of Nephrology : JASN2008
Complement 5a receptor inhibition improves renal allograft survival.
Article in Journal of the American Society of Nephrology : JASN, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 115 citations in OpenAlex.
- Article
- Role of intrarenal complement production in kidney transplantation.Clinical kidney journal · 2025Review
- METTL3 Potentiates M2 Macrophage-Driven MMT to Aggravate Renal Allograft Fibrosis via the TGF-β1/Smad3 Pathway.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Animal models for transplant immunology: bridging bench to bedside.Clinical transplantation and research · 2024Review
- Delayed graft function post renal transplantation: a review on animal models and therapeutics.American journal of physiology. Renal physiology · 2023Review
- The Complement System in Kidney Transplantation.Cells · 2023Review
- Innate immune modulation in transplantation: mechanisms, challenges, and opportunities.Frontiers in transplantation · 2023Review
- Activation of C3 and C5 May Be Involved in the Inflammatory Progression of PCM and GM.Inflammation · 2022Article
- Aspects of the Complement System in New Era of Xenotransplantation.Frontiers in immunology · 2022Review
- Complement-targeted therapies in kidney transplantation-insights from preclinical studies.Frontiers in immunology · 2022Review
- Inhibition of complement activation by CD55 overexpression in human induced pluripotent stem cell derived kidney organoids.Frontiers in immunology · 2022Article
- Role of Complement System in Kidney Transplantation: Stepping From Animal Models to Clinical Application.Frontiers in immunology · 2022Review
- Graft rejection markers in children undergoing hematopoietic cell transplant for bone marrow failure.Blood advances · 2021Article
- Role of C5aR1 and C5L2 Receptors in Ischemia-Reperfusion Injury.Journal of clinical medicine · 2021Article
- Minimizing Ischemia Reperfusion Injury in Xenotransplantation.Frontiers in immunology · 2021Review
- Inflammaging and Complement System: A Link Between Acute Kidney Injury and Chronic Graft Damage.Frontiers in immunology · 2020Review
- Mechanisms of haemolysis-induced kidney injury.Nature reviews. Nephrology · 2019Review
- High Concentration of C5a-Induced Mitochondria-Dependent Apoptosis in Murine Kidney Endothelial Cells.International journal of molecular sciences · 2019Article
- Chemokine CXCL13 as a New Systemic Biomarker for B-Cell Involvement in Acute T Cell-Mediated Kidney Allograft Rejection.International journal of molecular sciences · 2019Article
- The innate immune response to allotransplants: mechanisms and therapeutic potentials.Cellular & molecular immunology · 2019Review
Corrections and comments
- Commented on by
Authors and funding
13 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Complement activation plays a key role in mediating apoptosis, inflammation, and transplant rejection. In this study, the role of the complement 5a receptor (C5aR) was examined in human renal allografts and in an allogenic mouse model of renal transplant rejection. In human kidney transplants with acute rejection, C5aR expression was increased in renal tissue and in cells infiltrating the tubulointerstitium. Similar findings were observed in mice. When recipient mice were treated once daily with a C5aR antagonist before transplantation, long-term renal allograft survival was markedly improved compared with vehicle-treatment (75 versus 0%), and apoptosis was reduced. Furthermore, treatment with a C5aR antagonist significantly attenuated monocyte/macrophage infiltration, perhaps a result of reduced levels of monocyte chemoattractant protein 1 and the intercellular adhesion molecule 1. In vitro, C5aR antagonism inhibited intercellular adhesion molecule 1 upregulation in primary mouse aortic endothelial cells and reduced adhesion of peripheral blood mononuclear cells. Furthermore, C5aR blockade markedly reduced alloreactive T cell priming. These results demonstrate that C5aR plays an important role in mediating acute kidney allograft rejection, suggesting that pharmaceutical targeting of C5aR may have potential in transplantation medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.